Seres Therapeutics (MCRB) Non Operating Income (2014 - 2026)

Seres Therapeutics has reported Non Operating Income for 13 years, with the latest figure at $994000.0 in Q1 2026.

• Quarterly Non Operating Income fell 98.34% year-over-year to $994000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.7 million (down 24.45% YoY) and the FY2025 annual result came in at $99.7 million, up 2336.69% from the prior year.
• Non Operating Income slipped to $994000.0 in Q1 2026 per MCRB's latest filing, from $4.0 million in the prior quarter.
• Over five years, Non Operating Income peaked at $59.9 million in Q1 2025 and troughed at -$21.9 million in Q3 2024.
• A 5-year average of $5.6 million and a median of $1.5 million in 2024 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Non Operating Income plunged 712.29% in 2024, then surged 3803.45% in 2025.
• Over 5 years, Non Operating Income stood at -$489000.0 in 2022, then soared by 571.78% to $2.3 million in 2023, then soared by 472.08% to $13.2 million in 2024, then plunged by 69.37% to $4.0 million in 2025, then sank by 75.41% to $994000.0 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $994000.0, $4.0 million, and $30.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.